a composition comprising one or more protein agents, the one or more protein agents include one or more albumins selected from the group consisting of lactalbumins and serum albumins; one or more carbohydrate agents, the one or more carbohydrate agents include trehalose; and one or more poly(ethylene oxide) and poly(propylene oxide) (EO-PO) block copolymers, the one or more EO-PO block copolymers include poloxamer 407 (Pluronic F127®); wherein the composition decreases inactivation of a live, attenuated virus.

20. The kit of claim 19, wherein the EO-PO block copolymer is poloxamer 407, at least one protein agent is serum albumin, and the carbohydrate agent is trehalose.

21. The kit of claim 20, wherein the trehalose concentration is from 5 to 50% (w/v).

22. The kit of claim 20, wherein the poloxamer 407 concentration is from 0.1 to 4% (w/v).

23. The kit of claim 20, wherein the serum albumin concentration is from 0.001 to 3% (w/v).

24. The kit of claim 19, wherein the composition further comprises one or more live, attenuated viruses.

25. The kit of claim 24, wherein the live, attenuated viruses are selected from the group consisting of Flavivirus, Togavirus, Coronavirus, Rhabdovirus, Filovirus, Paramyxovirus, Orthomyxovirus, Bunyavirus, Arenavirus, Retrovirus, Hepadnavirus, Herpesvirus, Poxvirus families and combinations thereof.

26. A live attenuated virus composition comprising:

one or more live, attenuated viruses;

one or more co-polymer including poloxamer 407; having a concentration ~~of 4%~~from 0.1 to 4% (w/v) ~~or less~~;

one or more serum albumin having a concentration from 0.001 to 3% (w/v) and

one or more carbohydrate agents, the one or more carbohydrate agents include trehalose having a